Read on for the MHRA's position on whether Seroxat is addictive or not.
On the 15th December 2007 I wrote to the MHRA. It was a brief email and asked one simple question.. Is Seroxat addictive?
Basically, I pretty much knew what their answer would be - I just didn't expect to have to go round the houses before they finally acknowledged their position on Seroxat. Only 4 emails but hey what do you expect from them!
----- Original Message -----
From: fiddaman
To: MHRA Information Centre
Sent: Saturday, December 15, 2007 7:04 AM
Subject: Dear Sirs
Simple question that merely requires a yes or no answer. This shouldn't take 20 working days to answer.
Is Seroxat addictive?
Regards
Bob Fiddaman
----
----- Original Message -----
From: MHRA Information Centre
To: fiddaman
Sent: Thursday, December 20, 2007 10:15 AM
Subject: RE: Dear Sirs
Dear Mr Fiddaman,
Thank you for your recent enquiry to the MHRA.
The Agency's position, informed by expert advice, on whether Seroxat is addictive has been clearly communicated in the report of the CSM Expert Working Group on the Safety of SSRIs - this report is available on the MHRA website at the below link:
http://www.mhra.gov.uk/home/idcplg?IdcService=SS_GET_PAGE&nodeId=242
Please contact me again if you need further assistance with this, or any other queries.
Kind Regards,
Central Enquiry Point Information Centre Medicines and Healthcare products Regulatory Agency Tel: 020 7084 2000
----
----- Original Message -----
From: fiddaman
To: MHRA Information Centre
Sent: Thursday, December 20, 2007 2:32 PM
Subject: Re: Dear Sirs
Dear Sir/Madam,
Could you point me to the paragraph where an official MHRA statement has been made as to whether Seroxat is addictive or not.
I have trawled through the paper and cannot see any such statement. Maybe I'm missing something?
As you are aware GlaxoSmithKline have now realeased the European Promotion of Medicines Code of Practice 2nd Edition 2007 in which it states on page 6 (clause 4 - 4.10) "It must not be stated that a product has no side-effects, toxic hazards or risks of addiction or dependency."
If the MHRA say Seroxat isn't addictive (I don't know whether you have because I can't find any official statement) then do they (MHRA) still stand by this comment?
Basically, this email is a follow-up to my original question of whether the MHRA think Seroxat is addictive.
1. I cannot find any official MHRA statement in the link you sent me, please point me to the paragraph and
2. If the MHRA have stated in the past that Seroxat is not addictive, do they still stand by this, given the European Medicine of Medicines Code of Practice 2nd Edition 2007 clearly states that it must not be stated that a product has no side-effects, toxic hazards or risks of addiction or dependency?
Meantime, I look forward to you reply
Regards
Mr Robert Fiddaman.
----
----- Original Message -----
From: MHRA Information Centre
To: fiddaman
Sent: Monday, December 31, 2007 11:39 AM
Subject: RE: Dear Sirs
Dear Mr Fiddaman,
Thank you for your recent enquiry to the MHRA. The risk of dependence (addiction) and withdrawal reactions in associations with Seroxat and others SSRIs was covered in Chapter 8 - pages 119-157 and is also covered in the executive summary pages 3-4 of the report.
Please contact us again if you need further assistance with this, or any other queries.
Kind Regards,
Central Enquiry Point Information Centre Medicines and Healthcare products Regulatory Agency Tel: 020 7084 2000
----
----- Original Message -----
From: fiddaman
To: MHRA Information Centre
Sent: Tuesday, January 01, 2008 5:10 PM
Subject: Re: Dear Sirs
Thank you for pointing me to the correct statement. However, you have still failed to answer whether or not this is still the MHRA's position on the subject of addiction/dependency.
Is it?
Regards
Bob Fiddaman
----
----- Original Message -----
From: MHRA Information Centre
To: fiddaman
Sent: Thursday, January 03, 2008 10:40 AM
Subject: RE: Dear Sirs
Dear Bob Fiddaman,
Thank you for your recent enquiry to the MHRA. We can confirm that this is the latest MHRA position on the subject of addiction/dependency.
Please contact us again if you need further assistance with this, or any other queries.
Kind Regards,
Central Enquiry PointInformation CentreMedicines and Healthcare products Regulatory AgencyTel: 020 7084 2000
----
So there you have it ladies and gentlemen. The MHRA still stand by a report made some years ago, a report made without raw data being analysed.
You will notice that they... or probably their legal team will not answer yes or no as yes and no are definitive answers.
Now let me draw your attention to the following document on GlaxoSmithKline's webpage.
GSK European Promotion of Medicines Code of Practice 2nd Edition 2007.
Page 6: (Clause 4 - 4.10) "It must not be stated that a product has no side-effects, toxic hazards or risks of addiction or dependency."
Unless of course you work for the MHRA!
Over to you Kent
Zantac Lawsuit
Researching drug company and regulatory malfeasance for over 16 years
Humanist, humorist
Tuesday, January 15, 2008
Monday, January 14, 2008
KENT WOODS CEO of The MHRA 'Ignorance is Bliss'
Well Prof. Kent Woods, CEO of the MHRA has already told me via email that he/MHRA have nothing further to add regarding the safety of Seroxat in adults. I've offered to help the MHRA investigate GlaxoSmithKline, I think they are vast approaching their fifth year now? Their excuse? They have over a million documents to trawl through, pretty much the amount of pages I have trawled through in less than a year Kent! And I am only one, YOU have a whole fucking team of 'experts' behind you!
Well it seems Woods is just a stubborn man, he does not want to be proved wrong, he does not want his image tarnished by the likes of a patient/sufferer with a grievance. Maybe, he just does not like to be told what to do?
I am not the only one astounded by his lack of understanding.
Janne Larsson has also felt the need to write to Kent Woods regarding his lack... or rather the MHRA's lack of due care and attention to the ADHD drug, Strattera. Janne's letter gives updated information about the harmful effects of the ADHD drug Strattera.
Janne tells Kent Woods 'For the years 2004-2006 there have been 31,835 adverse reactions for Strattera reported to the FDA (where Strattera was the primary suspect drug) in 9,250 individual cases (with duplicate reports excluded) [2]. This puts Strattera as number three among most reported psychiatric drugs.'
Janne goes on to tell Kent Woods ' Despite "compelling evidence" for a causal association between Strattera and treatment emergent symptoms of psychosis or mania – no action by the MHRA
Is all this beginning to sound like Déjà vu ?
Here we have a campaigner with hard evidence who is being ignored by the CEO of the MHRA whose promise, on their webpage, is - "…we take any necessary action to protect the public promptly if there is a problem.
I'd just love to know how Kent Woods and the MHRA define the word 'Promptly'
Promptly = four and a half years investigating GSK.
Janne's full letter can be downloaded HERE
The letter should embarrass Woods - then again reality has to dawn on someone before they know they are wrong. Stubbornness is standing in the way of Woods making any decisions, that and the fact that as CEO of the MHRA he has finances to think of - if he were to speak out against Pharma the MHRA could forfeit the funding they receive off them.
Do us ALL a favour Kent - RESIGN
Well it seems Woods is just a stubborn man, he does not want to be proved wrong, he does not want his image tarnished by the likes of a patient/sufferer with a grievance. Maybe, he just does not like to be told what to do?
I am not the only one astounded by his lack of understanding.
Janne Larsson has also felt the need to write to Kent Woods regarding his lack... or rather the MHRA's lack of due care and attention to the ADHD drug, Strattera. Janne's letter gives updated information about the harmful effects of the ADHD drug Strattera.
Janne tells Kent Woods 'For the years 2004-2006 there have been 31,835 adverse reactions for Strattera reported to the FDA (where Strattera was the primary suspect drug) in 9,250 individual cases (with duplicate reports excluded) [2]. This puts Strattera as number three among most reported psychiatric drugs.'
Janne goes on to tell Kent Woods ' Despite "compelling evidence" for a causal association between Strattera and treatment emergent symptoms of psychosis or mania – no action by the MHRA
Is all this beginning to sound like Déjà vu ?
Here we have a campaigner with hard evidence who is being ignored by the CEO of the MHRA whose promise, on their webpage, is - "…we take any necessary action to protect the public promptly if there is a problem.
I'd just love to know how Kent Woods and the MHRA define the word 'Promptly'
Promptly = four and a half years investigating GSK.
Janne's full letter can be downloaded HERE
The letter should embarrass Woods - then again reality has to dawn on someone before they know they are wrong. Stubbornness is standing in the way of Woods making any decisions, that and the fact that as CEO of the MHRA he has finances to think of - if he were to speak out against Pharma the MHRA could forfeit the funding they receive off them.
Do us ALL a favour Kent - RESIGN
Sunday, January 13, 2008
Seroxat Withdrawal Book - Author wants stories
Shelly Hart is pissed off.
Another victim of Seroxat withdrawal and all the unhappiness it brings.
She is standing up to be counted.
She wrote me:
I need stories (good or bad although I haven't heard a good one yet) of Paxil withdrawal, attempted suicides coming off paxil, deaths of loved ones discontinuing paxil, etc. This book will be about Paxil as an addiction. Gsk must be accountable. I have the resources to get the book out there, I just need the people to come forward. Of course it can be anonymous and they can approve the final edit of their story. In the meantime, I'm looking for any information I can about the history of GSK and figuring a way to write it up without being sued. By having a book of personal stories, the word is out there, people are aware, they are aware that we will not stay quiet, and hopefully we can save some lives.
I admire people with balls, so if you want to email Shelly your stories please don't hesitate to contact her HERE
...Or pass her email address on to people you know who have suffered at the hands of GlaxoSmithKline's money earner.
hart.shelly@yahoo.com
You owe it to yourselves and to those less fortunate (those who actually have faith in the MHRA, FDA and GSK)
Fid
Another victim of Seroxat withdrawal and all the unhappiness it brings.
She is standing up to be counted.
She wrote me:
I need stories (good or bad although I haven't heard a good one yet) of Paxil withdrawal, attempted suicides coming off paxil, deaths of loved ones discontinuing paxil, etc. This book will be about Paxil as an addiction. Gsk must be accountable. I have the resources to get the book out there, I just need the people to come forward. Of course it can be anonymous and they can approve the final edit of their story. In the meantime, I'm looking for any information I can about the history of GSK and figuring a way to write it up without being sued. By having a book of personal stories, the word is out there, people are aware, they are aware that we will not stay quiet, and hopefully we can save some lives.
I admire people with balls, so if you want to email Shelly your stories please don't hesitate to contact her HERE
...Or pass her email address on to people you know who have suffered at the hands of GlaxoSmithKline's money earner.
hart.shelly@yahoo.com
You owe it to yourselves and to those less fortunate (those who actually have faith in the MHRA, FDA and GSK)
Fid
Saturday, January 05, 2008
My Mom
My beautiful mother died yesterday. She was 79.
I won't be posting for a while.
Times like this I wish I has a God to believe in.
Fid
I won't be posting for a while.
Times like this I wish I has a God to believe in.
Fid
Friday, January 04, 2008
Lets focus on the MHRA
I have a series of posts for you all concerning Kent Woods and his bunch of merry men over at MHRA HQ. I'm going to start with something simple that will put you all in the picture of just how the MHRA work. What are their motives etc.
Here is the blurb for a book written by Jim Wright, a book entitled 'The Fate of a Good Man'
It will highlight for you all just how far the MHRA will go to protect the financial ties they have with Pharma.
Here's the blurb:
The Fate of a Good Man follows the fortunes of Jim Wright, a man who thought that he could help with the health of his community by distributing and selling natural treatments for a variety of conditions. Instead of being seen as a good citizen, someone of value in the community, Jim Wright was investigated, prosecuted and tried by the Medicines and Health products Regulation Agency, a firm within the Government that is totally funded by the pharmaceutical industry and that will go to any lengths to see off the ‘competition’
Jim Wright and his family were raided twice over a three-year period, before eventually being charged on twelve counts. In the trial that ensued at Swansea Crown Court, the prosecuting counsel, hired by the MHRA and not the Crown Prosecution Service, said that Wright was dishonest, a hypocrite and a liar, a man who would do anything to make a quick pound, a man who preyed on vulnerable sick people. The Fate of A Good Man gives Jim Wright’s version of how he was hounded and then put on trial by Big Pharma.
Coming soon: Janne Larsson's gripe with Prof. Kent Woods, CEO of the MHRA
Here is the blurb for a book written by Jim Wright, a book entitled 'The Fate of a Good Man'
It will highlight for you all just how far the MHRA will go to protect the financial ties they have with Pharma.
Here's the blurb:
The Fate of a Good Man follows the fortunes of Jim Wright, a man who thought that he could help with the health of his community by distributing and selling natural treatments for a variety of conditions. Instead of being seen as a good citizen, someone of value in the community, Jim Wright was investigated, prosecuted and tried by the Medicines and Health products Regulation Agency, a firm within the Government that is totally funded by the pharmaceutical industry and that will go to any lengths to see off the ‘competition’
Jim Wright and his family were raided twice over a three-year period, before eventually being charged on twelve counts. In the trial that ensued at Swansea Crown Court, the prosecuting counsel, hired by the MHRA and not the Crown Prosecution Service, said that Wright was dishonest, a hypocrite and a liar, a man who would do anything to make a quick pound, a man who preyed on vulnerable sick people. The Fate of A Good Man gives Jim Wright’s version of how he was hounded and then put on trial by Big Pharma.
Coming soon: Janne Larsson's gripe with Prof. Kent Woods, CEO of the MHRA
Inspirational words from Obama Barrack
Heard his speech from his victory in Iowa yesterday and thought the following words were applicable for those of us who are stonewalled by GSK and the MHRA.
Hope is not blind optimism.
Hope is the thing inside us that insists, despite all the evidence to the contrary, that something better awaits us if we have the courage to reach for it and to work for it and to fight for it. Hope is the belief that our destiny will not be written for us but by us.
Obama Barrack
Iowa Victroy Speech 03/01/08
Hope is not blind optimism.
Hope is the thing inside us that insists, despite all the evidence to the contrary, that something better awaits us if we have the courage to reach for it and to work for it and to fight for it. Hope is the belief that our destiny will not be written for us but by us.
Obama Barrack
Iowa Victroy Speech 03/01/08
Thursday, January 03, 2008
COMING SOON...
My recent correspondence with the MHRA regarding whether or not Seroxat is addictive. Also a brilliant open letter to the CEO of the MHRA, Kent Woods, regarding the ADHD drug Strattera. The letter was penned by Janne Larsson and shows just how the MHRA have failed to act on the dangers of yet another mind altering drug.
I'll post both my correspondence and Janne's within the next 24 hours.
May I suggest that Kent Woods do the honourable thing and resign from his position
Fid
I'll post both my correspondence and Janne's within the next 24 hours.
May I suggest that Kent Woods do the honourable thing and resign from his position
Fid
The GlaxoSmithKline Payroll Part II
Judith A. Aberg, M.D., Director of HIV Services, Washington University, St. Louis, MO. Received funding for clinical research from Abbott Laboratories and Agouron; serves on the speakers bureau for Merck and Fujisawa (now Astellas Pharma US). (http://www.thebodypro.com/bios/jaberg.html, accessed 1/24/07) Received grants for educational activities from and/or served as an advisor or consultant to Abbott, Bristol-Myers Squibb, Boehringer Ingelheim, Gilead, GlaxoSmithKline, and Roche. (http://www.medscape.com/viewarticle/513050, accessed 1/24/07)
----
Martin J. Abrahamson, M.D., Associate Professor, Harvard Medical School, Boston, MA. Acting Chief Medical Officer, Joslin Diabetes Center, Boston, MA. Receives research grants from Pfizer Inc.; member of the speaker's bureaus for AstraZeneca Pharmaceuticals LP, Aventis Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Merck & Co., Novo Nordisk, Novartis, Pfizer Inc, and Takeda Pharmaceuticals North America. (http://www.medscape.com/viewprogram/3942_authors; accessed 7/28/05)
----
Kirkwood F. Adams, M.D., Associate Professor of Medicine and Radiology, University of North Carolina, Chapel Hill, NC. Received research support from Actelion Pharmaceuticals U.S., Inc., Amgen, Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, GlaxoSmithKline, Myogen, Inc., Novartis Pharmaceuticals Corporation, NitroMed, Inc., NovaCardia, Inc., Otsuka America Pharmaceutical, Inc., Scios Inc., and Vasogen Inc. Consultant to Abbott Laboratories, Amgen, Inc., AstraZeneca Pharmaceuticals LP, Biosite, Inc., Bristol-Myers Squibb, GlaxoSmithKline, Myogen, Inc., Otsuka America Pharmaceutical, Inc., Pfizer Inc., Sanofi-Synthelabo Inc., and Scios Inc. (http://www.medscape.com/viewprogram/4088_authors; accessed 7/28/05)
----
Jasjit S. Ahluwalia, M.D., M.P.H., Professor of Preventive Medicine and Public Health and Professor of Internal Medicine, University of Kansas, Kansas City. Served as consultant to GlaxoSmithKline. (Evans, Jeff. Sustained-Release bupropion boosts smoking cessation in African Americans, Family Practice News, 1/1/03, p.12)
EMAIL
----
Hagop S. Akiskal, M.D., Professor of Psychiatry, Director of the International Mood Center, University of California at San Diego, La Jolla. Received grant or research support from Eli Lilly. Served as a consultant to Abbott, Janssen Pharmaceutica, and Eli Lilly. Served on the speakers’ bureaus of Abbott, GlaxoSmithKline, Janssen Pharmaceutica, and Eli Lilly. (http://www.wpic.pitt.edu/STANLEY/5thbipconf/introduction.htm; accessed 5/27/05)
EMAIL
----
George S. Alexopoulos, M.D., Professor of Psychiatry at Weill Medical College, Cornell University, Ithaca, NY. Receives honoraria from Cephalon. (http://www.psychiatrist.com/audiograph/stahl/indexc.htm; accessed 3/4/04) Receives grant/research support from Forest Laboratories and Cephalon; consultant to Forest Laboratories; and member of the speakers bureau for Forest Laboratories, Eli Lilly, Pfizer, GlaxoSmithKline, and Janssen. (Conference disclosure notes; 41st Annual Meeting of the American College of Neuropsychopharmacology, December 2002, San Juan, Puerto Rico; on file with CSPI)
EMAIL
----
Lori Altshuler, M.D., Professor and Director, Mood Disorders Research Program, University of California, Los Angeles. Grants/research support from Abbott Laboratories, Eli Lilly, Forest Labs, Glaxo-Wellcome, SmithKlineBeecham, and Solvay. Consultant to Abbott Laboratories, Eli Lilly, Forest Labs, Janssen, Parke Davis, and Bristol Myers Squibb. Member,speakers bureaus of Abbott Laboratories, Eli Lilly, Glaxo-Wellcome, and Solvay. Scientfic Advisory Board for Abbott Laboratories, Eli Lilly, and Forest Labs. (Conference disclosure notes: 41st Annual Meeting of the American College of Neuropsychopharmacology, December 2002, San Juan, Puerto Rico; on file with CSPI; Primary Care Companion J Clin Psychiatry. 2000; 2:217-23)
----
Jean Anderson, M.D., Professor, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD. Serves on the advisory board, speakers bureau, receives research support from, and holds stock in Pfizer; received honoraria from GlaxoSmithKline and Abbott Laboratories; receives educational program support from GlaxoSmithKline, Abbott Laboratories, Boehringer Ingelheim, and Pfizer. (http://www.guideline.gov/summary/summary.aspx?doc_id=9868, accessed 1/26/07)
----
Janet B. Arrowsmith-Lowe, M.D., F.A.C.P., Partner, Arrowsmith-Lowe Consulting. Works for a consulting company whose clients include Bayer, GlaxoSmithKline, Merck, Pfizer, and Wyeth. (http://www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4090T2.htm; accessed 7/8/05)
EMAIL
----
Michael E. Aulton, B.Pharm., Ph.D., M.R.Pharm.S., Professor of Pharmaceutical Technology and Head of Graduate School, De Montfort University, Bedford, UK. Patent advice consultancy with Pfizer from Jan. to Feb. 2002. Receives research grant funding from GlaxoSmithKline, R.P. Scherer, Pfizer and AstraZeneca. (http://www.mca.gov.uk/aboutagency/regframework/csm/csmdoi01.pdf; accessed 7/18/03)
Part I HERE
Source:- Integrity in Science
----
Martin J. Abrahamson, M.D., Associate Professor, Harvard Medical School, Boston, MA. Acting Chief Medical Officer, Joslin Diabetes Center, Boston, MA. Receives research grants from Pfizer Inc.; member of the speaker's bureaus for AstraZeneca Pharmaceuticals LP, Aventis Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, GlaxoSmithKline, Merck & Co., Novo Nordisk, Novartis, Pfizer Inc, and Takeda Pharmaceuticals North America. (http://www.medscape.com/viewprogram/3942_authors; accessed 7/28/05)
----
Kirkwood F. Adams, M.D., Associate Professor of Medicine and Radiology, University of North Carolina, Chapel Hill, NC. Received research support from Actelion Pharmaceuticals U.S., Inc., Amgen, Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, GlaxoSmithKline, Myogen, Inc., Novartis Pharmaceuticals Corporation, NitroMed, Inc., NovaCardia, Inc., Otsuka America Pharmaceutical, Inc., Scios Inc., and Vasogen Inc. Consultant to Abbott Laboratories, Amgen, Inc., AstraZeneca Pharmaceuticals LP, Biosite, Inc., Bristol-Myers Squibb, GlaxoSmithKline, Myogen, Inc., Otsuka America Pharmaceutical, Inc., Pfizer Inc., Sanofi-Synthelabo Inc., and Scios Inc. (http://www.medscape.com/viewprogram/4088_authors; accessed 7/28/05)
----
Jasjit S. Ahluwalia, M.D., M.P.H., Professor of Preventive Medicine and Public Health and Professor of Internal Medicine, University of Kansas, Kansas City. Served as consultant to GlaxoSmithKline. (Evans, Jeff. Sustained-Release bupropion boosts smoking cessation in African Americans, Family Practice News, 1/1/03, p.12)
----
Hagop S. Akiskal, M.D., Professor of Psychiatry, Director of the International Mood Center, University of California at San Diego, La Jolla. Received grant or research support from Eli Lilly. Served as a consultant to Abbott, Janssen Pharmaceutica, and Eli Lilly. Served on the speakers’ bureaus of Abbott, GlaxoSmithKline, Janssen Pharmaceutica, and Eli Lilly. (http://www.wpic.pitt.edu/STANLEY/5thbipconf/introduction.htm; accessed 5/27/05)
----
George S. Alexopoulos, M.D., Professor of Psychiatry at Weill Medical College, Cornell University, Ithaca, NY. Receives honoraria from Cephalon. (http://www.psychiatrist.com/audiograph/stahl/indexc.htm; accessed 3/4/04) Receives grant/research support from Forest Laboratories and Cephalon; consultant to Forest Laboratories; and member of the speakers bureau for Forest Laboratories, Eli Lilly, Pfizer, GlaxoSmithKline, and Janssen. (Conference disclosure notes; 41st Annual Meeting of the American College of Neuropsychopharmacology, December 2002, San Juan, Puerto Rico; on file with CSPI)
----
Lori Altshuler, M.D., Professor and Director, Mood Disorders Research Program, University of California, Los Angeles. Grants/research support from Abbott Laboratories, Eli Lilly, Forest Labs, Glaxo-Wellcome, SmithKlineBeecham, and Solvay. Consultant to Abbott Laboratories, Eli Lilly, Forest Labs, Janssen, Parke Davis, and Bristol Myers Squibb. Member,speakers bureaus of Abbott Laboratories, Eli Lilly, Glaxo-Wellcome, and Solvay. Scientfic Advisory Board for Abbott Laboratories, Eli Lilly, and Forest Labs. (Conference disclosure notes: 41st Annual Meeting of the American College of Neuropsychopharmacology, December 2002, San Juan, Puerto Rico; on file with CSPI; Primary Care Companion J Clin Psychiatry. 2000; 2:217-23)
----
Jean Anderson, M.D., Professor, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD. Serves on the advisory board, speakers bureau, receives research support from, and holds stock in Pfizer; received honoraria from GlaxoSmithKline and Abbott Laboratories; receives educational program support from GlaxoSmithKline, Abbott Laboratories, Boehringer Ingelheim, and Pfizer. (http://www.guideline.gov/summary/summary.aspx?doc_id=9868, accessed 1/26/07)
----
Janet B. Arrowsmith-Lowe, M.D., F.A.C.P., Partner, Arrowsmith-Lowe Consulting. Works for a consulting company whose clients include Bayer, GlaxoSmithKline, Merck, Pfizer, and Wyeth. (http://www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4090T2.htm; accessed 7/8/05)
----
Michael E. Aulton, B.Pharm., Ph.D., M.R.Pharm.S., Professor of Pharmaceutical Technology and Head of Graduate School, De Montfort University, Bedford, UK. Patent advice consultancy with Pfizer from Jan. to Feb. 2002. Receives research grant funding from GlaxoSmithKline, R.P. Scherer, Pfizer and AstraZeneca. (http://www.mca.gov.uk/aboutagency/regframework/csm/csmdoi01.pdf; accessed 7/18/03)
Part I HERE
Source:- Integrity in Science
Wednesday, January 02, 2008
The first 2008 Seroxat Sufferers Dumbass Award goes to...
... Covalence
Geneva-based Covalence tracks the ethical reputation of multinationals by sourcing information from companies, the media and civil society. EthicalQuote allows you to browse CSR rankings and data and it enables us to offer reputation management products to clients among multinationals, investors and institutions.
Lets have a look at the top 10 list of the most ethical Pharmas for 2007
Best EthicalQuote Score
1.GlaxoSmithKline (GSK)
2.Johnson & Johnson (JNJ)
3.Bristol Myers Squibb (BMS)
4.Abbott (ABT)
5.Novartis (NVS)
6.Roche (RHHBY.PK)
7.Boehringer Ingelheim
8.Astra Zeneca (AZN)
9.Pfizer (PFE)
10.Sanofi Aventis (SNY)
You have got to be kidding right?
GlaxoSmithKline ethical?
Ethical:- Being in accordance with the accepted principles of right and wrong that govern the conduct of a profession. See Synonyms at moral.
This is some kind of joke right?
Hang on a minute... I smell a rather large rat
Wanna smell it with me folks?
Well lookey here
Scroll down the page and you will see that the compilers of the 'ethical' list have many clients - one of whom are non other than GlaxoSmithKline!
Covalence - I hereby award you with the prestigious Seroxat Sufferers Dumbass Award
Geneva-based Covalence tracks the ethical reputation of multinationals by sourcing information from companies, the media and civil society. EthicalQuote allows you to browse CSR rankings and data and it enables us to offer reputation management products to clients among multinationals, investors and institutions.
Lets have a look at the top 10 list of the most ethical Pharmas for 2007
Best EthicalQuote Score
1.GlaxoSmithKline (GSK)
2.Johnson & Johnson (JNJ)
3.Bristol Myers Squibb (BMS)
4.Abbott (ABT)
5.Novartis (NVS)
6.Roche (RHHBY.PK)
7.Boehringer Ingelheim
8.Astra Zeneca (AZN)
9.Pfizer (PFE)
10.Sanofi Aventis (SNY)
You have got to be kidding right?
GlaxoSmithKline ethical?
Ethical:- Being in accordance with the accepted principles of right and wrong that govern the conduct of a profession. See Synonyms at moral.
This is some kind of joke right?
Hang on a minute... I smell a rather large rat
Wanna smell it with me folks?
Well lookey here
Scroll down the page and you will see that the compilers of the 'ethical' list have many clients - one of whom are non other than GlaxoSmithKline!
Covalence - I hereby award you with the prestigious Seroxat Sufferers Dumbass Award
COVALENCE...YOU ARE DUMBASSES!
Previous winners
Google Adsense
Mylan Inc
Mr Keith Lyon Meloff
Depressionet Australia
The GlaxoSmithKline Payroll Part I
The following 'specialists', doctors, call them what you will, have all had ties with GlaxoSmithKline be it through sitting on panels or receiving funding. Maybe it's time they were asked to explain what the word 'Morals' means?
Hagop S. Akiskal, M.D., Professor of Psychiatry, Director of the International Mood Center, University of California at San Diego, La Jolla. Received grant or research support from Eli Lilly. Served as a consultant to Abbott, Janssen Pharmaceutica, and Eli Lilly. Served on the speakers’ bureaus of Abbott, GlaxoSmithKline, Janssen Pharmaceutica, and Eli Lilly. (http://www.wpic.pitt.edu/STANLEY/5thbipconf/introduction.htm; accessed 5/27/05)
EMAIL
----
David B. Badesch, M.D., F.C.C.P., Professor of Medicine and Clinical Director, Pulmonary Hypertension Center, University of Colorado Health Sciences Center, Denver. Served as a consultant or on a speakers bureau for Glaxo Wellcome/GlaxoSmithKline, Actelion, InterMune, Encysive, Myogen, Astra-Merck, AstraZeneca, Exhale Therapeutics/CoTherix, Forrest Labs, INO Therapeutics, and Berlex. Received research support from Glaxo Wellcome/GlaxoSmithKline, United Therapeutics, Boehringer Ingelheim, Actelion, Encysive, ICOS/Texas Biotechnologies/Encysive, Myogen, INO Therapeutics, Scleroderma Foundation, United Therapeutics, and Pfizer. (Chest 2004;126:1)
EMAIL
----
David A. Baker, M.D., Professor, Obstetrics, Gynecology, and Reproductive Medicine, and Director, Division of Infectious Diseases, Health Sciences Center, Stony Brook University, Stony Brook, NY. Speaker and researcher for GlaxoSmithKline. (Am J Obstet Gynecol. 2005; 193:1887-8.)
----
George L. Bakris, M.D., Professor of Internal Medicine and Preventive Medicine, Department of Preventive Medicine, Rush-Presbyterian-St. Luke Medical Center, Chicago. Advisor to Abbott Laboratories, Alteon Inc., AstraZeneca Pharmaceuticals LP, AusAm Biotechnologies, Inc., Biovail Corporation, BMS-Sanofi, Boehringer Ingelheim Pharmaceuticals Inc., Eli Lilly & Company, Forest Laboratories, GlaxoSmithKline, Merck & Co., Novartis Pharmaceuticals, Inc., Takeda Pharmaceuticals North America, Inc., and Wyeth Pharmaceuticals; received research support from Abbott Laboratories, Alteon Inc., AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc., Eli Lilly & Company, Forest Laboratories, GlaxoSmithKline, Merck & Company, Inc., and Novartis Pharmaceuticals, Inc.; member of the speakers' bureaus of Abbott Laboratories, Alteon Inc., AstraZeneca Pharmaceuticals LP, AusAm Biotechnologies, Inc., Biovail Corporation, BMS-Sanofi, Boehringer Ingelheim Pharmaceuticals Inc., Eli Lilly & Company, Forest Laboratories, GlaxoSmithKline, Merck & Company, Inc., Novartis Pharmaceuticals, Inc., Takeda Pharmaceuticals North America, Inc., and Wyeth Pharmaceuticals. (http://www.medscape.com/viewprogram/3599_authors; accessed 7/28/05) Received grants, served as a consultant to, and received honoraria for serving as a speaker from AstraZeneca, Abbott, Alteon, Biovail, Boehringer-Ingelheim, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Merck, Novartis, Sankyo, Sanofi and Solvay. (JAMA. 2003;289:2560-72.)
EMAIL
----
Robyn J. Barst, M.D., Director, New York Presbyterian Pulmonary Hypertension Center, New York, NY. Served as a consultant and received research support from Actelion, Encysive, Exhale Therapeutics, INO, Myogen, United Therapeutics, Pfizer and GlaxoSmithKline. Received unrestricted education grants from GlaxoSmithKline, Encysive, and Actelion. (Chest 2004;126:1)
EMAIL
----
Robert B. Belshe, M.D., Professor, Director, Division of Infectious Disease and Immunology, Saint Louis University, St. Louis, MO. Receives research support from Merck and MedImmune; receives consulting fees and/or lecture fees from MedImmune, Merck, Novartis, GlaxoSmithKline, and Sanofi. (N Engl J Med. 2007 Feb 15;356(7):685-96.)
----
Constance A. Benson, M.D., Professor of Medicine, Division of Infectious Diseases, University of California San Diego, and Member, Board of Directors, International AIDS Society–USA. Served as a scientific advisor to Boehringer Ingelheim, GlaxoSmithKline, Johnson & Johnson, Merck, and Tibotec. (http://www.iasusa.org/people/disclosure.html; accessed 11/7/06)
EMAIL
----
Karl R. Beutner, M.D., Ph.D., Chief Medical Officer, Solano Clinical Research, Dow Pharmaceutical Sciences. Also, Associate Clinical Professor, Department of Dermatology, University of California, San Francisco. Research on the use of Valtrex (valacyclovir) to reduce the risk of transmission of genital herpes partially funded by GlaxoSmithKline Research and Development. Received consultation and lecture fees from GlaxoSmithKline, Eli Lilly, and 3M. (N. Engl. J. Med. 2003;350:11-22)
----
Alison Blenkinsopp, Ph.D., Professor of Medicines Management, Keele University, Newcastle, England. Received research funding from Servier, Pfizer, GlaxoSmithKline, and Merck Sharp & Dohme Ltd. (http://www.mca.gov.uk/aboutagency/regframework/csm/csmdoi01.pdf; accessed 7/18/03)
----
Charles L. Bowden, M.D., Professor and Chairman, Department of Psychiatry, University of Texas Health Science Center, San Antonio. Received grant or research support from Abbott, Bristol-Myers Squibb, Glaxo Wellcome, Janssen Pharmaceutica, Lilly Research, Parke-Davis, and SmithKline Beecham. Served as a consultant for Abbott, Glaxo Wellcome, Janssen Pharmaceutica, Lilly Research, Sanofi Synthelabo, and UCB Pharma. Served on the speakers’ bureau of Abbott Laboratories, Astra Zeneca, Glaxo Wellcome, Janssen Pharmaceutica, Lilly Research, and Pfizer. (http://www.wpic.pitt.edu/STANLEY/5thbipconf/introduction.htm; accessed 5/27/05) “Olanzapine in the Treatment of Recently Unresponsive Manic Illness” funded by Eli Lilly. (http://psychiatry.uthscsa.edu/Searches/SearchProfileData.asp?ID=24; accessed 3/4/05) Consultant for Abbott Laboratories, GlaxoSmithKline, Janssen, Ortho-McNeil, Eli Lilly, Sanofi-Synthelabo and UCB Pharma. Receives grant support from Abbott Laboratories, Bristol-Myers Squibb, Elan Pharmaceuticals, SmithKline Beecham (now GlaxoSmithKline), Janssen, Parke-Davis, and Eli Lilly and is a member of the speakers bureau for AstraZeneca, GlaxoSmithKline, Janssen, Eli Lilly, Pfizer, Ortho-McNeil and Sanofi Synthelabo. (Neuropsychopharmacology 2003;28:1374-82.; Conference disclosure notes; 41st Annual Meeting of the American College of Neuropsychopharmacology, December 2002, San Juan, Puerto Rico; on file with CSPI)
EMAIL
More coming soon.
Source: Integrity in Science
Hagop S. Akiskal, M.D., Professor of Psychiatry, Director of the International Mood Center, University of California at San Diego, La Jolla. Received grant or research support from Eli Lilly. Served as a consultant to Abbott, Janssen Pharmaceutica, and Eli Lilly. Served on the speakers’ bureaus of Abbott, GlaxoSmithKline, Janssen Pharmaceutica, and Eli Lilly. (http://www.wpic.pitt.edu/STANLEY/5thbipconf/introduction.htm; accessed 5/27/05)
----
David B. Badesch, M.D., F.C.C.P., Professor of Medicine and Clinical Director, Pulmonary Hypertension Center, University of Colorado Health Sciences Center, Denver. Served as a consultant or on a speakers bureau for Glaxo Wellcome/GlaxoSmithKline, Actelion, InterMune, Encysive, Myogen, Astra-Merck, AstraZeneca, Exhale Therapeutics/CoTherix, Forrest Labs, INO Therapeutics, and Berlex. Received research support from Glaxo Wellcome/GlaxoSmithKline, United Therapeutics, Boehringer Ingelheim, Actelion, Encysive, ICOS/Texas Biotechnologies/Encysive, Myogen, INO Therapeutics, Scleroderma Foundation, United Therapeutics, and Pfizer. (Chest 2004;126:1)
----
David A. Baker, M.D., Professor, Obstetrics, Gynecology, and Reproductive Medicine, and Director, Division of Infectious Diseases, Health Sciences Center, Stony Brook University, Stony Brook, NY. Speaker and researcher for GlaxoSmithKline. (Am J Obstet Gynecol. 2005; 193:1887-8.)
----
George L. Bakris, M.D., Professor of Internal Medicine and Preventive Medicine, Department of Preventive Medicine, Rush-Presbyterian-St. Luke Medical Center, Chicago. Advisor to Abbott Laboratories, Alteon Inc., AstraZeneca Pharmaceuticals LP, AusAm Biotechnologies, Inc., Biovail Corporation, BMS-Sanofi, Boehringer Ingelheim Pharmaceuticals Inc., Eli Lilly & Company, Forest Laboratories, GlaxoSmithKline, Merck & Co., Novartis Pharmaceuticals, Inc., Takeda Pharmaceuticals North America, Inc., and Wyeth Pharmaceuticals; received research support from Abbott Laboratories, Alteon Inc., AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc., Eli Lilly & Company, Forest Laboratories, GlaxoSmithKline, Merck & Company, Inc., and Novartis Pharmaceuticals, Inc.; member of the speakers' bureaus of Abbott Laboratories, Alteon Inc., AstraZeneca Pharmaceuticals LP, AusAm Biotechnologies, Inc., Biovail Corporation, BMS-Sanofi, Boehringer Ingelheim Pharmaceuticals Inc., Eli Lilly & Company, Forest Laboratories, GlaxoSmithKline, Merck & Company, Inc., Novartis Pharmaceuticals, Inc., Takeda Pharmaceuticals North America, Inc., and Wyeth Pharmaceuticals. (http://www.medscape.com/viewprogram/3599_authors; accessed 7/28/05) Received grants, served as a consultant to, and received honoraria for serving as a speaker from AstraZeneca, Abbott, Alteon, Biovail, Boehringer-Ingelheim, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Merck, Novartis, Sankyo, Sanofi and Solvay. (JAMA. 2003;289:2560-72.)
----
Robyn J. Barst, M.D., Director, New York Presbyterian Pulmonary Hypertension Center, New York, NY. Served as a consultant and received research support from Actelion, Encysive, Exhale Therapeutics, INO, Myogen, United Therapeutics, Pfizer and GlaxoSmithKline. Received unrestricted education grants from GlaxoSmithKline, Encysive, and Actelion. (Chest 2004;126:1)
----
Robert B. Belshe, M.D., Professor, Director, Division of Infectious Disease and Immunology, Saint Louis University, St. Louis, MO. Receives research support from Merck and MedImmune; receives consulting fees and/or lecture fees from MedImmune, Merck, Novartis, GlaxoSmithKline, and Sanofi. (N Engl J Med. 2007 Feb 15;356(7):685-96.)
----
Constance A. Benson, M.D., Professor of Medicine, Division of Infectious Diseases, University of California San Diego, and Member, Board of Directors, International AIDS Society–USA. Served as a scientific advisor to Boehringer Ingelheim, GlaxoSmithKline, Johnson & Johnson, Merck, and Tibotec. (http://www.iasusa.org/people/disclosure.html; accessed 11/7/06)
----
Karl R. Beutner, M.D., Ph.D., Chief Medical Officer, Solano Clinical Research, Dow Pharmaceutical Sciences. Also, Associate Clinical Professor, Department of Dermatology, University of California, San Francisco. Research on the use of Valtrex (valacyclovir) to reduce the risk of transmission of genital herpes partially funded by GlaxoSmithKline Research and Development. Received consultation and lecture fees from GlaxoSmithKline, Eli Lilly, and 3M. (N. Engl. J. Med. 2003;350:11-22)
----
Alison Blenkinsopp, Ph.D., Professor of Medicines Management, Keele University, Newcastle, England. Received research funding from Servier, Pfizer, GlaxoSmithKline, and Merck Sharp & Dohme Ltd. (http://www.mca.gov.uk/aboutagency/regframework/csm/csmdoi01.pdf; accessed 7/18/03)
----
Charles L. Bowden, M.D., Professor and Chairman, Department of Psychiatry, University of Texas Health Science Center, San Antonio. Received grant or research support from Abbott, Bristol-Myers Squibb, Glaxo Wellcome, Janssen Pharmaceutica, Lilly Research, Parke-Davis, and SmithKline Beecham. Served as a consultant for Abbott, Glaxo Wellcome, Janssen Pharmaceutica, Lilly Research, Sanofi Synthelabo, and UCB Pharma. Served on the speakers’ bureau of Abbott Laboratories, Astra Zeneca, Glaxo Wellcome, Janssen Pharmaceutica, Lilly Research, and Pfizer. (http://www.wpic.pitt.edu/STANLEY/5thbipconf/introduction.htm; accessed 5/27/05) “Olanzapine in the Treatment of Recently Unresponsive Manic Illness” funded by Eli Lilly. (http://psychiatry.uthscsa.edu/Searches/SearchProfileData.asp?ID=24; accessed 3/4/05) Consultant for Abbott Laboratories, GlaxoSmithKline, Janssen, Ortho-McNeil, Eli Lilly, Sanofi-Synthelabo and UCB Pharma. Receives grant support from Abbott Laboratories, Bristol-Myers Squibb, Elan Pharmaceuticals, SmithKline Beecham (now GlaxoSmithKline), Janssen, Parke-Davis, and Eli Lilly and is a member of the speakers bureau for AstraZeneca, GlaxoSmithKline, Janssen, Eli Lilly, Pfizer, Ortho-McNeil and Sanofi Synthelabo. (Neuropsychopharmacology 2003;28:1374-82.; Conference disclosure notes; 41st Annual Meeting of the American College of Neuropsychopharmacology, December 2002, San Juan, Puerto Rico; on file with CSPI)
More coming soon.
Source: Integrity in Science
Tuesday, January 01, 2008
Coronation Street - 'Liz McDonald' memory loss when on Seroxat
Despite her collapse and diagnosis, Beverley returned to work the next day, hoping the drug would make her feel better, although she had been warned it could be six weeks before it took effect.
'Actually, I felt worse as the weeks went on. I never forgot my lines, but an hour after a conversation, I wouldn't remember what had been said.'
FULL STORY
Subscribe to:
Posts (Atom)
Please contact me if you would like a guest post considered for publication on my blog.